Q&A: COVID-19 a 'pivot point' for pharma policy

Reporting on the 2021 Access to Medicine Index, Catherine Cheney for Devex focuses on the shift of eight pharmaceutical companies towards integrating access planning into their R&D pipelines and the factors which have contributed to this industry shift since 2018.

During a Q&A session with Jayasree Iyer, Catherine asks about the role of the COVID-19 pandemic in the pharmaceutical companies' change of approach and whether the remaining 12 companies will engage in systematic access planning. She then makes reference to Pfizer which has newly joined the top five and goes on to find out the reasons for this progress.

Read the Q&A session here.